Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers

被引：41

作者：

Lo Re M. ^{[1
]}

Capobianco M. ^{[2
]}

Ragonese P. ^{[1
]}

Realmuto S. ^{[1
]}

Malucchi S. ^{[2
]}

Berchialla P. ^{[3
]}

Salemi G. ^{[1
]}

Bertolotto A. ^{[2
]}

机构：

[1] Department of Experimental Biomedicine and Clinical Neurosciences, University of Palermo, Palermo

[2] Regional Multiple Sclerosis Centre, San Luigi Gonzaga Hospital, Orbassano

[3] Department of Clinical and Biological Sciences, University of Turin, Torino

来源：

Neurology and Therapy | 2015年 / 4卷 / 2期

关键词：

Disease reactivation; First-line therapies; Multiple sclerosis; Natalizumab discontinuation; Rebound; Second-line therapies;

D O I：

10.1007/s40120-015-0038-9

中图分类号：

学科分类号：

摘要：

Introduction: Natalizumab (NTZ) discontinuation can be followed by multiple sclerosis (MS) disease reactivation. Currently no disease-modifying drug (DMD) has been shown to be able to abolish disease reactivation. The aims of the current study were: (1) to determine the frequency of MS reactivation after NTZ discontinuation; (2) to evaluate predictors of reactivation risk, and (3) to compare the effect of different treatments in reducing this risk. Methods: Data from 132 patients with MS followed-up for 2 years before NTZ treatment and 1 year after interruption were collected from two Italian MS centers and retrospectively evaluated. Results: Overall, 72 of 132 patients (54.5%) had relapses after NTZ discontinuation and 60 of 125 patients (48%), who had magnetic resonance imaging, had radiological reactivation. Rebound was observed in 28 of 132 patients (21.2%). A higher number of relapses in the 2 years before NTZ treatment, a longer washout period, and a lower number NTZ infusions correlated with reactivation and rebound. Untreated patients (n = 37) had higher clinical and radiological activity and rebound in comparison to patients receiving DMDs. Moreover, a lower risk of relapses was found in patients treated with second-line therapies (NTZ and fingolimod) than in those treated with first-line therapies (interferon beta, glatiramer acetate, teriflunomide, azathioprine). Interestingly, no disease reactivation in off-label treatment (rituximab, autologous hematopoietic stem cell transplantation) was observed. Conclusion: NTZ discontinuation is a risk for MS reactivation and rebound. An alternative treatment should be promptly resumed mainly in patients with a previous very active disease course and with a shorter NTZ therapy. Second-line therapies demonstrate superiority in preventing relapses after NTZ discontinuation. © 2015, The Author(s).

引用

页码：147 / 157

页数：10

共 37 条

[1]

Polman C.H., O'Connor P.W., Havrdova E., Et al., A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med, 354, pp. 899-910, (2006)

[2]

Rudick R.A., Stuart W.H., Calabresi P.A., Et al., Natalizumab plus interferon beta 1-a for relapsing multiple sclerosis, N Engl J Med, 354, pp. 911-923, (2006)

[3]

Baldwin K.J., Hogg J.P., Progressive multifocal leukoencephalopathy in patients with multiple sclerosis, Curr Opin Neurol, 26, pp. 318-3223, (2013)

[4]

Berger J.R., Aksamit A.J., Clifford D.B., Et al., PML diagnostic criteria, Neurology, 80, pp. 1430-1438, (2013)

[5]

Sorensen S., Bertolotto A., Edan G., Et al., Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab, Mult Scler, 18, 2, pp. 143-152, (2012)

[6]

Fox R.J., Cree B.A., De Seze J., Et al., MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study, Neurology, 82, pp. 1491-1498, (2014)

[7]

O'Connor P.W., Goodman A., Kappos L., Et al., Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis, Neurology, 76, pp. 1858-1865, (2011)

[8]

Berger J.R., Centonze D., Comi G., Et al., Considerations on discontinuing natalizumab for the treatment of multiple sclerosis, Ann Neurol, 68, 3, pp. 409-410, (2010)

[9]

Sangalli F., Moiola L., Ferre L., Et al., Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients, Mult Scler Relat Disord, 3, pp. 520-526, (2014)

[10]

Killestein J., Vennegoor A., Strijbis E.M., Et al., Natalizumab drug holiday in multiple sclerosis: poorly tolerated, Ann Neurol, 68, pp. 392-395, (2010)

← 1 2 3 4 →